Cost minimization comparison of oral UFT/leucovorin versus 5-fluorouracil/leucovorin as adjuvant therapy for colorectal cancer in Taiwan
Abstract
Aim: Oral uracil–tegafur/leucovorin (UFT/LV) and intravenous 5-fluorouracil (FU)/LV are common adjuvant therapies for Stages II and III colorectal cancer. This study aims to determine the most cost-effective treatment alternative between UFT/LV and 5-FU/LV in Stages II and III colorectal cancer from Taiwan's National Health Insurance perspective. Patients & methods: The costs were referenced directly from the National Health Insurance reimbursement price. Chemotherapy regimen considered for the cost analysis calculation was adapted from NSABP-C-06 study, and, a time saving calculation was also included. In addition, we compare the treatment outcome. Result: A total cost saving of US$3620.80–$3709.16 per patient per treatment was achieved with the UFT/LV treatment. UFT/LV provides the comparable outcome to 5-FU/LV. Conclusion: UFT/LV was the more cost-effective treatment as adjuvant chemotherapy.
Supplementary Material
File (supplementary content.docx)
- Download
- 41.57 KB
References
1.
Health Promotion Administration Ministry of Health and Welfare: Cancer Registry Annual Report 2015, Taiwan. Published date: January (2017).
2.
Sargent D, Sobrero A, Grothey A et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J. Clin. Oncol. 27, 872–877 (2009).
3.
Tanaka F. UFT (tegafur and uracil) as postoperative adjuvant chemotherapy for solid tumors (carcinoma of the lung, stomach, colon/rectum, and breast): clinical evidence, mechanism of action, and future direction. Surg. Today 37, 923–943 (2007).
4.
Hoff PM, Pazdur R. UFT plus oral leucovorin: a new oral treatment for colorectal cancer. Oncologist 3, 155–164 (1998).
5.
Kato T, Ohashi Y, Nakazato H et al. Efficacy of oral UFT as adjuvant chemotherapy to curative resection of colorectal cancer: multicenter prospective randomized trial. Langenbecks Arch. Surg. 386, 575–581 (2002).
6.
Lin BR, Lai HS, Chang TC, Lee PH, Chang KJ, Liang JT. Long-term survival results of surgery alone versus surgery plus UFT (uracil and tegafur)-based adjuvant therapy in patients with Stage II colon cancer. J. Gastrointest. Surg. 15, 2239–2245 (2011).
7.
Lembersky BC, Wieand HS, Petrelli NJ et al. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J. Clin. Oncol. 24, 2059–2064 (2006).
8.
Douillard JY, Hoff PM, Skillings JR et al. Multicenter Phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. 20, 3605–3616 (2002).
9.
Carmichael J, Popiela T, Radstone D et al. Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. 20, 3617–3627 (2002).
10.
Hsieh CH, Chen YJ, Chang KH et al. Post-operative concurrent chemoradiation therapy using oral uracil–tegafur versus weekly intravenous fluorouracil for locally advanced rectal cancer. Anticancer Res. 26, 3709–3715 (2006).
11.
2012 Taiwan Cancer Registry Briefing: five year survival rate for cancer. www.hpa.gov.tw/Pages/ashx/File.ashx?FilePath=∼/File/Attach/2892/File_3646.pdf.
12.
Hsu TC, Chen HH, Yang MC et al. Pharmacoeconomic analysis of capecitabine versus 5-fluorouracil/leucovorin as adjuvant therapy for Stage III colon cancer in Taiwan. Value Health 14, 647–651 (2011).
13.
Shiroiwa T, Fukuda T, Shimozuma K, Ohashi Y, Tsutani K. Cost–effectiveness analysis of capecitabine compared with bolus 5-fluorouracil/l-leucovorin for the adjuvant treatment of colon cancer in Japan. Pharmacoeconomics 27, 597–608 (2009).
14.
Norum J, Vonen B, Olsen JA, Revhaug A. Adjuvant chemotherapy (5-fluorouracil and levamisole) in Dukes’ B and C colorectal carcinoma. A cost–effectiveness analysis. Ann. Oncol. 8, 65–70 (1997).
15.
Ward S, Kaltenthaler E, Cowan J, Brewer N. Clinical and cost–effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation. Health Technol. Assess. 7, 1–93 (2003).
16.
Maroun J, Asche C, Romeyer F et al. A cost comparison of oral tegafur plus uracil/folinic acid and parenteral fluorouracil for colorectal cancer in Canada. Pharmacoeconomics 21, 1039–1051 (2003).
17.
Murad A, de Andrade CA, Delfino C, Arikian S, Doyle J, Sinha N. A pharmacoeconomic comparison of UFT and 5-FU chemotherapy for colorectal cancer in South America. Oncology (Williston Park) 11, 128–135 (1997).
18.
Fabian CJ, Reddy E, Jewell W et al. Phase I-II pilot of whole abdominal radiation and concomitant 5-FU as an adjuvant in colon cancer: a Southwest Oncology Group Study. Int. J. Radiat. Oncol. Biol. Phys. 15, 885–892 (1988).
19.
Internal Revenue Service: Yearly average currency exchange rates translating foreign currency into US dollars. www.irs.gov/Individuals/International-Taxpayers/Yearly-Average-Currency-Exchange-Rates.
20.
Kopec JA, Yothers G, Ganz PA et al. Quality of life in operable colon cancer patients receiving oral compared with intravenous chemotherapy: results from National Surgical Adjuvant Breast and Bowel Project Trial C-06. J. Clin. Oncol. 25, 424–430 (2007).
21.
Ollendorf D. Impact of uracil/tegafur plus oral calcium folinate on resource utilization. Oncology (Williston Park) 13, 42–43 (1999).
22.
Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J. Clin. Oncol. 15, 110–115 (1997).
23.
Borner MM, Schoffski P, de Wit R et al. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur. J. Cancer 38, 349–358 (2002).
Information & Authors
Information
Published In
Copyright
© 2018 Future Medicine Ltd.
History
Received: 22 July 2018
Accepted: 8 November 2018
Published online: 18 December 2018
Keywords:
Topics
Authors
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
Cost minimization comparison of oral UFT/leucovorin versus 5-fluorouracil/leucovorin as adjuvant therapy for colorectal cancer in Taiwan. (2018) Journal of Comparative Effectiveness Research. DOI: 10.2217/cer-2018-0078
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- Kun-Yao Dai, Fred Yi-Shueh Chen, Chien-Kuo Liu, Johnson Lin, Shih-Hua Liu, Preoperative Chemoradiotherapy with Tegafur-Uracil, Capecitabine, or 5-Fluorouracil/Leucovorin for Rectal Cancer in an Asian Cohort: A Real-World Comparison from the Pre-TNT Era, Current Oncology, 10.3390/curroncol33020079, 33, 2, (79), (2026).
- Yat Hang To, Peter Gibbs, Jeanne Tie, Maarten IJzerman, Koen Degeling, Health economic evidence for adjuvant chemotherapy in stage II and III colon cancer: a systematic review, Cost Effectiveness and Resource Allocation, 10.1186/s12962-023-00422-2, 21, 1, (2023).
- Naoko A Ronquest, Kyle Paret, Aaron Lucas, Malgorzata Ciepielewska, Melissa Hagan, Quantifying the Value of Introducing an Oral Drug Delivery Option for Edaravone: A Review of Analyses Evaluating the Economic Impact of Oral versus Intravenous Formulations, ClinicoEconomics and Outcomes Research, 10.2147/CEOR.S359025, Volume 14, (499-511), (2022).
- Po-Huang Chen, Yi-Ying Wu, Cho-Hao Lee, Chi-Hsiang Chung, Yu-Guang Chen, Tzu-Chuan Huang, Ren-Hua Yeh, Ping-Ying Chang, Ming-Shen Dai, Shiue-Wei Lai, Ching-Liang Ho, Jia-Hong Chen, Yeu-Chin Chen, Je-Ming Hu, Sung-Sen Yang, Wu-Chien Chien, Uracil-tegafur vs fluorouracil as postoperative adjuvant chemotherapy in Stage II and III colon cancer, Medicine, 10.1097/MD.0000000000025756, 100, 18, (e25756), (2021).